Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 674

1.

Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.

Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong J, Anavekar N, Anker SD, Arango JL, Arenas JL, Atar D, Ben-Gal T, Boytsov SA, Chen CH, Chopra VK, Cleland J, Comin-Colet J, Duengen HD, Echeverría Correa LE, Filippatos G, Flammer AJ, Galinier M, Godoy A, Goncalvesova E, Janssens S, Katova T, Køber L, Lelonek M, Linssen G, Lund LH, O'Meara E, Merkely B, Milicic D, Oh BH, Perrone SV, Ranjith N, Saito Y, Saraiva JF, Shah S, Seferovic PM, Senni M, Sibulo AS Jr, Sim D, Sweitzer NK, Taurio J, Vinereanu D, Vrtovec B, Widimský J Jr, Yilmaz MB, Zhou J, Zweiker R, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV.

Circ Heart Fail. 2018 Jul;11(7):e004962. doi: 10.1161/CIRCHEARTFAILURE.118.004962.

PMID:
29980595
2.

Questioning the obvious: does dyspnoea really matter in heart failure?

Packer M.

Eur Heart J. 2018 Jun 22. doi: 10.1093/eurheartj/ehy354. [Epub ahead of print] No abstract available.

PMID:
29939237
3.

Prospective multicenter clinical trial to evaluate the safety and effectiveness of a new glistening-free one-piece acrylic toric intraocular lens.

Packer M, Williams JI, Feinerman G, Hope RS.

Clin Ophthalmol. 2018 Jun 1;12:1031-1039. doi: 10.2147/OPTH.S167726. eCollection 2018.

4.

Risk of heart failure in diabetic patients receiving sulfonylureas: reply.

Packer M.

Eur J Heart Fail. 2018 Jun 11. doi: 10.1002/ejhf.1232. [Epub ahead of print] No abstract available.

PMID:
29888457
5.

Building Castles in the Sky: Catheter Ablation in Patients With Atrial Fibrillation and Chronic Heart Failure.

Packer M, Kowey PR.

Circulation. 2018 May 30. pii: CIRCULATIONAHA.118.034583. doi: 10.1161/CIRCULATIONAHA.118.034583. [Epub ahead of print]

PMID:
29848750
6.

Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium.

Packer M.

J Am Coll Cardiol. 2018 May 22;71(20):2360-2372. doi: 10.1016/j.jacc.2018.03.509. Review.

PMID:
29773163
7.

Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure).

O'Meara E, Prescott MF, Claggett B, Rouleau JL, Chiang LM, Solomon SD, Packer M, McMurray JJV, Zile MR.

Circ Heart Fail. 2018 May;11(5):e004446. doi: 10.1161/CIRCHEARTFAILURE.117.004446.

PMID:
29748349
8.
9.

Publisher Correction: Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage.

Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, Liu DR.

Nature. 2018 May 2. doi: 10.1038/s41586-018-0070-x. [Epub ahead of print]

PMID:
29720650
10.
11.

Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.

Packer M, Claggett B, Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, Zile MR.

Lancet Diabetes Endocrinol. 2018 Jul;6(7):547-554. doi: 10.1016/S2213-8587(18)30100-1. Epub 2018 Apr 13.

PMID:
29661699
12.

Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.

Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Swedberg K, Zile MR, Packer M, Desai AS, Solomon SD, McMurray JJV.

JACC Heart Fail. 2018 Jun;6(6):489-498. doi: 10.1016/j.jchf.2018.02.004. Epub 2018 Apr 11.

13.
14.
15.

Potential mechanisms underlying differences in the effect of incretin-based antidiabetic drugs on the risk of major atherosclerotic ischemic events.

Packer M.

J Diabetes Complications. 2018 Jun;32(6):616-617. doi: 10.1016/j.jdiacomp.2018.03.006. Epub 2018 Mar 24. No abstract available.

PMID:
29627373
16.

Does a Target Dose or a Target Heart Rate Matter to Outcomes When Prescribing β-Blockers to Patients With Chronic Heart Failure?

Packer M.

Circ Cardiovasc Qual Outcomes. 2018 Apr;11(4):e004605. doi: 10.1161/CIRCOUTCOMES.118.004605. No abstract available.

PMID:
29622595
17.

Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.

Chandra A, Lewis EF, Claggett BL, Desai AS, Packer M, Zile MR, Swedberg K, Rouleau JL, Shi VC, Lefkowitz MP, Katova T, McMurray JJV, Solomon SD.

JAMA Cardiol. 2018 Jun 1;3(6):498-505. doi: 10.1001/jamacardio.2018.0398.

PMID:
29617523
18.

Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure.

Packer M.

Eur J Heart Fail. 2018 Jun;20(6):973-977. doi: 10.1002/ejhf.1185. Epub 2018 Mar 30. Review.

PMID:
29603541
19.

Brain and behavioral correlates of insulin resistance in youth with depression and obesity.

Singh MK, Leslie SM, Packer MM, Zaiko YV, Phillips OR, Weisman EF, Wall DM, Jo B, Rasgon N.

Horm Behav. 2018 Apr 5. pii: S0018-506X(17)30501-9. doi: 10.1016/j.yhbeh.2018.03.009. [Epub ahead of print]

PMID:
29596854
20.

Greenshell™ Mussels: A Review of Veterinary Trials and Future Research Directions.

Eason CT, Adams SL, Puddick J, Romanazzi D, Miller MR, King N, Johns S, Forbes-Blom E, Hessian PA, Stamp LK, Packer MA.

Vet Sci. 2018 Mar 27;5(2). pii: E36. doi: 10.3390/vetsci5020036. Review.

21.
22.
23.
24.
25.

Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.

Packer M, Kitzman DW.

JACC Heart Fail. 2018 Mar 7. pii: S2213-1779(18)30062-3. doi: 10.1016/j.jchf.2018.01.009. [Epub ahead of print] Review.

PMID:
29525327
26.

Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure.

Vaduganathan M, Claggett B, Packer M, McMurray JJV, Rouleau JL, Zile MR, Swedberg K, Solomon SD.

JACC Heart Fail. 2018 Jul;6(7):564-569. doi: 10.1016/j.jchf.2018.02.007. Epub 2018 Mar 4.

PMID:
29501807
27.

Derangements in adrenergic-adipokine signalling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction.

Packer M.

Eur J Heart Fail. 2018 May;20(5):873-878. doi: 10.1002/ejhf.1167. Epub 2018 Mar 1. Review.

PMID:
29493068
28.

Do Most Obese People with Exercise Intolerance and a Normal Ejection Fraction Have Treatable Heart Failure?

Packer M.

Am J Med. 2018 Mar 27. pii: S0002-9343(18)30115-3. doi: 10.1016/j.amjmed.2018.01.038. [Epub ahead of print] No abstract available.

PMID:
29477710
29.
30.

Heart Rate Variability Markers as Correlates of Survival in Recipients of Hematopoietic Cell Transplantation

Scheiber C, Johnston L, Packer M, Gevirtz R, Edwards KS, Palesh O.

Oncol Nurs Forum. 2018 Mar 1;45(2):250-259. doi: 10.1188/18.ONF.250-259.

PMID:
29466350
31.

Data sharing in medical research.

Packer M.

BMJ. 2018 Feb 14;360:k510. doi: 10.1136/bmj.k510. No abstract available.

PMID:
29444885
32.

Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity? Clues From Laboratory Models and Clinical Trials.

Packer M.

Circ Res. 2018 Mar 30;122(7):928-932. doi: 10.1161/CIRCRESAHA.118.312673. Epub 2018 Feb 7. Review.

PMID:
29436388
33.

Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).

Mogensen UM, Gong J, Jhund PS, Shen L, Køber L, Desai AS, Lefkowitz MP, Packer M, Rouleau JL, Solomon SD, Claggett BL, Swedberg K, Zile MR, Mueller-Velten G, McMurray JJV.

Eur J Heart Fail. 2018 Apr;20(4):760-768. doi: 10.1002/ejhf.1139. Epub 2018 Feb 12.

PMID:
29431251
34.

Are physicians neglecting the risk of heart failure in diabetic patients who are receiving sulfonylureas? Lessons from the TOSCA.IT trial.

Packer M.

Eur J Heart Fail. 2018 Jan;20(1):49-51. doi: 10.1002/ejhf.1093. No abstract available.

PMID:
29388338
35.
36.
38.

Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?

Packer M.

Am J Med. 2018 May;131(5):461-463. doi: 10.1016/j.amjmed.2017.11.052. Epub 2018 Jan 5. No abstract available.

PMID:
29309741
39.

Is the Popularity of Dipeptidyl-Peptidase-4 Inhibitors Justified? Insights From Mechanistic Studies and Clinical Trials.

Packer M.

Am J Med. 2018 Jul;131(7):e287-e289. doi: 10.1016/j.amjmed.2017.11.055. Epub 2018 Jan 4. No abstract available.

PMID:
29307538
40.

Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?

Packer M.

J Card Fail. 2018 Feb;24(2):109-111. doi: 10.1016/j.cardfail.2017.12.007. Epub 2018 Jan 3. No abstract available.

PMID:
29305970
41.

The Future Treatment of Heart Failure?

Packer M.

Eur Heart J. 2018 Jan 1;39(1):5-7. doi: 10.1093/eurheartj/ehx745. No abstract available.

PMID:
29300940
42.

Acute Heart Failure Is an Event Rather Than a Disease: Plea for a Radical Change in Thinking and in Therapeutic Drug Development.

Packer M.

JACC Heart Fail. 2018 Jan;6(1):73-75. doi: 10.1016/j.jchf.2017.05.008. Review. No abstract available.

PMID:
29284579
43.

Is metformin beneficial for heart failure in patients with type 2 diabetes?

Packer M.

Diabetes Res Clin Pract. 2018 Feb;136:168-170. doi: 10.1016/j.diabres.2017.12.011. Epub 2017 Dec 24.

PMID:
29278713
44.

Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes.

Packer M.

Diabetes Care. 2018 Jan;41(1):11-13. doi: 10.2337/dci17-0052. No abstract available.

PMID:
29263193
45.

Absence of an Ideal Observer II: The Agonizing Search for Experts Without a Conflict of Interest.

Packer M.

Circulation. 2017 Dec 19;136(25):2400-2402. doi: 10.1161/CIRCULATIONAHA.117.031200. No abstract available.

PMID:
29255120
46.

Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes.

Packer M.

Diabetes Obes Metab. 2018 Apr;20(4):800-811. doi: 10.1111/dom.13191. Epub 2018 Jan 17. Review.

PMID:
29227582
47.

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.

Mogensen UM, Køber L, Jhund PS, Desai AS, Senni M, Kristensen SL, Dukát A, Chen CH, Ramires F, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Solomon SD, Swedberg K, Packer M, McMurray JJV; PARADIGM-HF Investigators and Committees.

Eur J Heart Fail. 2018 Mar;20(3):514-522. doi: 10.1002/ejhf.1056. Epub 2017 Nov 30.

PMID:
29193563
48.

Role of Payers in the Development of Cardiovascular Therapeutics: Misalignment Between Approval and Reimbursement.

Zannad F, Alonso Garcia MLA, Borer JS, Stough WG, Clutton-Brock T, Rosenberg Y, Packer M.

J Am Coll Cardiol. 2017 Dec 5;70(22):2822-2830. doi: 10.1016/j.jacc.2017.10.027. Review.

PMID:
29191332
49.

Are Meta-Analyses a Form of Medical Fake News? Thoughts About How They Should Contribute to Medical Science and Practice.

Packer M.

Circulation. 2017 Nov 28;136(22):2097-2099. doi: 10.1161/CIRCULATIONAHA.117.030209. No abstract available.

PMID:
29180491
50.

Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage.

Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, Liu DR.

Nature. 2017 Nov 23;551(7681):464-471. doi: 10.1038/nature24644. Epub 2017 Oct 25. Erratum in: Nature. 2018 May 2;:.

Supplemental Content

Loading ...
Support Center